Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Bioage Labs Inc (BIOA)

Bioage Labs Inc (BIOA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates GlobeNewswire - Wed Aug 5, 3:50PM CDT

First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026...

BIOA : 10.50 (+0.38%)
BioAge Labs' Longevity Data Look Promising, but the Market Still Wants Revenue Barchart - Tue Aug 4, 4:05PM CDT

Barchart Research What to Expect from BIOA Earnings BIOA Generated August 4, 2026 Current Price $11.20 EPS Estimate $$-0.65 Consensus Rating Moderate Buy Average Move 5.38% BioAge Labs' Longevity Data...

BIOA : 10.50 (+0.38%)
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026 PR Newswire - Tue Jul 14, 10:39AM CDT

STOCKHOLM , July 14, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER)...

BIOA : 10.50 (+0.38%)
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk GlobeNewswire - Tue Jun 16, 7:00AM CDT

Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk...

BIOA : 10.50 (+0.38%)
MarketBeat.com
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease MarketBeat - Sat Jun 6, 7:04AM CDT

BioAge Labs (NASDAQ:BIOA) executives used a fireside chat at the Jefferies 2026 Global Healthcare Conference to outline the company’s plans for BGE-102, its lead NLRP3 inhibitor, with near-term readouts...

BIOA : 10.50 (+0.38%)
BioAge Labs to Present at Upcoming Investor Conferences GlobeNewswire - Fri May 22, 8:00AM CDT

EMERYVILLE, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic...

BIOA : 10.50 (+0.38%)
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets FinancialNewsMedia - Wed May 20, 8:45AM CDT

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:BIOA),(NYSE:LCTX),(NASDAQ:FATE) EQNX::TICKER_END

AVAI : 0.1200 (+4.26%)
BIOA : 10.50 (+0.38%)
LCTX : 1.1050 (+4.25%)
GERN : 1.5550 (+1.63%)
FATE : 2.66 (+3.91%)
BioAge Labs Enters Its First Quarter Judged Entirely on Pipeline Execution Barchart - Mon May 11, 4:02PM CDT

Barchart Research What to Expect from BIOA Earnings BIOA Generated May 11, 2026 Current Price $18.16 EPS Estimate $$-0.69 Consensus Rating Moderate Buy Average Move 6.27% BioAge Labs Enters Its First Quarter...

BIOA : 10.50 (+0.38%)
MarketBeat.com
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials MarketBeat - Fri May 8, 2:12PM CDT

BioAge Labs (NASDAQ:BIOA) used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant inhibitor of the NLRP3 inflammasome that the company is developing across cardiovascular...

BIOA : 10.50 (+0.38%)
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates GlobeNewswire - Fri May 8, 8:00AM CDT

Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk Phase 2 dose-ranging proof-of-concept...

BIOA : 10.50 (+0.38%)

Barchart Exclusives

Google Is Betting a Whopping $94 Billion on SpaceX Stock Barchart - 2 minutes ago
What does Google's $94 billion stake in SpaceX really mean? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.